Anti-SARS coronavirus agents: a patent review (2008 - present).
Identifieur interne : 002720 ( Ncbi/Curation ); précédent : 002719; suivant : 002721Anti-SARS coronavirus agents: a patent review (2008 - present).
Auteurs : Vathan Kumar ; Young-Sik Jung ; Po-Huang LiangSource :
- Expert opinion on therapeutic patents [ 1744-7674 ] ; 2013.
Descripteurs français
- KwdFr :
- ARN viral (), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Brevets comme sujet, Helicase (antagonistes et inhibiteurs), Humains, Immunothérapie, Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (usage thérapeutique), Syndrome respiratoire aigu sévère (traitement médicamenteux), Vaccins antiviraux (usage thérapeutique), Virus du SRAS ().
- MESH :
- antagonistes et inhibiteurs : Helicase.
- pharmacologie : Antiviraux, Inhibiteurs de protéases.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Inhibiteurs de protéases, Vaccins antiviraux.
- ARN viral, Animaux, Brevets comme sujet, Humains, Immunothérapie, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), DNA Helicases (antagonists & inhibitors), Humans, Immunotherapy, Patents as Topic, Protease Inhibitors (pharmacology), Protease Inhibitors (therapeutic use), RNA, Viral (drug effects), SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Viral Vaccines (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : DNA Helicases.
- chemical , drug effects : RNA, Viral.
- chemical , pharmacology : Antiviral Agents, Protease Inhibitors.
- chemical , therapeutic use : Antiviral Agents, Protease Inhibitors, Viral Vaccines.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- Animals, Humans, Immunotherapy, Patents as Topic.
Abstract
A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 and originated in southern China. SARS-CoV rapidly spread to > 30 countries by 2003, infecting nearly 8,000 people and causing around 800 fatalities. After 10 years of silence, a 2012 report alarmed researchers about the emergence of a new strain of CoV causing SARS-like disease.
DOI: 10.1517/13543776.2013.823159
PubMed: 23905913
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001157
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001157
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001229
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002720
Links to Exploration step
pubmed:23905913Curation
No country items
Vathan Kumar<affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation><wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-SARS coronavirus agents: a patent review (2008 - present).</title><author><name sortKey="Kumar, Vathan" sort="Kumar, Vathan" uniqKey="Kumar V" first="Vathan" last="Kumar">Vathan Kumar</name><affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation><wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry></affiliation></author><author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name></author><author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23905913</idno><idno type="pmid">23905913</idno><idno type="doi">10.1517/13543776.2013.823159</idno><idno type="wicri:Area/PubMed/Corpus">001157</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001157</idno><idno type="wicri:Area/PubMed/Curation">001157</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001157</idno><idno type="wicri:Area/PubMed/Checkpoint">001229</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001229</idno><idno type="wicri:Area/Ncbi/Merge">002720</idno><idno type="wicri:Area/Ncbi/Curation">002720</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-SARS coronavirus agents: a patent review (2008 - present).</title><author><name sortKey="Kumar, Vathan" sort="Kumar, Vathan" uniqKey="Kumar V" first="Vathan" last="Kumar">Vathan Kumar</name><affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation><wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry></affiliation></author><author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name></author><author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name></author></analytic><series><title level="j">Expert opinion on therapeutic patents</title><idno type="eISSN">1744-7674</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>DNA Helicases (antagonists & inhibitors)</term><term>Humans</term><term>Immunotherapy</term><term>Patents as Topic</term><term>Protease Inhibitors (pharmacology)</term><term>Protease Inhibitors (therapeutic use)</term><term>RNA, Viral (drug effects)</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral ()</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Brevets comme sujet</term><term>Helicase (antagonistes et inhibiteurs)</term><term>Humains</term><term>Immunothérapie</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Inhibiteurs de protéases (usage thérapeutique)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Helicases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Protease Inhibitors</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Helicase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéases</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Immunotherapy</term><term>Patents as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>ARN viral</term><term>Animaux</term><term>Brevets comme sujet</term><term>Humains</term><term>Immunothérapie</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 and originated in southern China. SARS-CoV rapidly spread to > 30 countries by 2003, infecting nearly 8,000 people and causing around 800 fatalities. After 10 years of silence, a 2012 report alarmed researchers about the emergence of a new strain of CoV causing SARS-like disease.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002720 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002720 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:23905913
|texte= Anti-SARS coronavirus agents: a patent review (2008 - present).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:23905913" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |